Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Rivera

Showing results (591-600 of 631) with videos related to

Pageof 64
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 17, 2014
Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trialE Élez, I Kocáková, T Höhler, et al.
Human Vaccines & Immunotherapeutics|August 6, 2024
Sociodemographic determinants of HPV vaccine awareness, uptake, and intention among parents of adolescents in France 2021-22Alexia F Rivera, Josée M Dussault, Damien Oudin Doglioni, et al.
ESMO Gastrointestinal Oncology|May 25, 2026
Dose optimization of immune checkpoint inhibitors for gastrointestinal malignanciesM Alsina, M Beunza-Sola, A Fernández-Montes, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|January 30, 2013
Panitumumab and irinotecan every 3 weeks is an active and convenient regimen for second-line treatment of patients with wild-type K-RAS metastatic colorectal cancerA Carrato, A Gómez, P Escudero, et al.
Journal of Dental Research|August 21, 2013
Bis-enoxacin inhibits bone resorption and orthodontic tooth movementE J Toro, J Zuo, A Gutierrez, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|March 1, 2017
Erratum to: Equity, barriers and cancer disparities: study of the Spanish Society of Medical Oncology on the access to oncologic drugs in the Spanish RegionsJ Salvador, J Aparicio, F J Baron, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 9, 2020
Corrigendum to 'Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE)': Annals of Oncology, Volume 31, Issue 1, 2020, Pages 79-87M Kundranda, A C Gracian, S F Zafar, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 9, 2020
Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE)M Kundranda, A C Gracian, S F Zafar, et al.
Blood Advances|April 6, 2021
Zinc-dependent multimerization of mutant calreticulin is required for MPL binding and MPN pathogenesisJeanne F Rivera, April J Baral, Fatima Nadat, et al.
Cell Biology International|May 4, 2019
The mRVG-9R peptide as a potential therapeutic vector to the central nervous system cellsSheila A Villa-Cedillo, Adolfo Soto-Domínguez, Humberto Rodríguez-Rocha, et al.
Pageof 64

Showing results (591-600 of 631) with videos related to

Sort By:
Pageof 64
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 17, 2014
Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trialE Élez, I Kocáková, T Höhler, et al.
Human Vaccines & Immunotherapeutics|August 6, 2024
Sociodemographic determinants of HPV vaccine awareness, uptake, and intention among parents of adolescents in France 2021-22Alexia F Rivera, Josée M Dussault, Damien Oudin Doglioni, et al.
ESMO Gastrointestinal Oncology|May 25, 2026
Dose optimization of immune checkpoint inhibitors for gastrointestinal malignanciesM Alsina, M Beunza-Sola, A Fernández-Montes, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|January 30, 2013
Panitumumab and irinotecan every 3 weeks is an active and convenient regimen for second-line treatment of patients with wild-type K-RAS metastatic colorectal cancerA Carrato, A Gómez, P Escudero, et al.
Journal of Dental Research|August 21, 2013
Bis-enoxacin inhibits bone resorption and orthodontic tooth movementE J Toro, J Zuo, A Gutierrez, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|March 1, 2017
Erratum to: Equity, barriers and cancer disparities: study of the Spanish Society of Medical Oncology on the access to oncologic drugs in the Spanish RegionsJ Salvador, J Aparicio, F J Baron, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 9, 2020
Corrigendum to 'Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE)': Annals of Oncology, Volume 31, Issue 1, 2020, Pages 79-87M Kundranda, A C Gracian, S F Zafar, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 9, 2020
Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE)M Kundranda, A C Gracian, S F Zafar, et al.
Blood Advances|April 6, 2021
Zinc-dependent multimerization of mutant calreticulin is required for MPL binding and MPN pathogenesisJeanne F Rivera, April J Baral, Fatima Nadat, et al.
Cell Biology International|May 4, 2019
The mRVG-9R peptide as a potential therapeutic vector to the central nervous system cellsSheila A Villa-Cedillo, Adolfo Soto-Domínguez, Humberto Rodríguez-Rocha, et al.
Pageof 64